Who are Control (insulin Novorapid)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ultra Rapid Lispro (URLi), Insulin lispro (Humalog), Faster Insulin Aspart (Fiasp®), insulin aspart + insulin aspart protamin, INSULIN GLULISINE (HMR1964), Insulin Lispro-aabc.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/control-insulin-novorapid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Control (insulin Novorapid) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Control (insulin Novorapid) (Control (insulin Novorapid)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rapid-acting insulin analog. Area: Diabetes.

phase 3 Rapid-acting insulin analog Insulin receptor (IR) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Control (insulin Novorapid) (Control (insulin Novorapid)) — Rigshospitalet, Denmark. Insulin aspart (NovoRapid) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Control (insulin Novorapid) TARGET	Control (insulin Novorapid)	Rigshospitalet, Denmark	phase 3	Rapid-acting insulin analog	Insulin receptor (IR)
Ultra Rapid Lispro (URLi)	Ultra Rapid Lispro (URLi)	Tel-Aviv Sourasky Medical Center	marketed	Rapid-acting insulin analog	Insulin receptor
Insulin lispro (Humalog)	Insulin lispro (Humalog)	Eli Lilly and Company	marketed	Rapid-acting insulin analog	Insulin receptor
Faster Insulin Aspart (Fiasp®)	Faster Insulin Aspart (Fiasp®)	Mountain Diabetes and Endocrine Center	marketed	Rapid-acting insulin analog	Insulin receptor
insulin aspart + insulin aspart protamin	insulin aspart + insulin aspart protamin	Steno Diabetes Center Copenhagen	marketed	Insulin (biphasic rapid-acting insulin analog)	Insulin receptor
INSULIN GLULISINE (HMR1964)	INSULIN GLULISINE (HMR1964)	Sanofi	marketed	Rapid-acting insulin analog	Insulin receptor
Insulin Lispro-aabc	Insulin Lispro-aabc	Eli Lilly and Company	marketed	Rapid-acting insulin analog	Insulin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rapid-acting insulin analog class)

Eli Lilly and Company · 12 drugs in this class
Sanofi · 6 drugs in this class
Novo Nordisk A/S · 4 drugs in this class
Rigshospitalet, Denmark · 2 drugs in this class
Mountain Diabetes and Endocrine Center · 1 drug in this class
Mylan Inc. · 1 drug in this class
Nanjing First Hospital, Nanjing Medical University · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Oxford University Hospitals NHS Trust · 1 drug in this class
Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Control (insulin Novorapid) — Competitive Intelligence Brief. https://druglandscape.com/ci/control-insulin-novorapid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab